Evidence map›Paper›PMID 39963330›Full record

ArticleFrontiers in allergy2024

EUFOREA meeting on defining disease states in allergic rhinitis: towards a unified language in AR.

G K Scadding, D M Conti, S Scheire, V Backer, M Blaiss, L O Cardell, W De Yun, A K Ellis, W Fokkens, A T Fox and 21 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in allergy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Turbinoplasty Versus Medical Treatment for Allergic Rhinitis: A Systematic Review and Meta-Analysis.World journal of otorhinolaryngology - head and neck surgery · 2026
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

G K ScaddingRoyal National ENT Hospital and University College, London, United Kingdom.
D M ContiEscuela de Doctorado UAM, Centro de Estudios de Posgrado, Universidad Autónoma de Madrid, Calle Francisco Tomás y Valiente, no. 2, Ciudad Universitaria de Cantoblanco, Madrid, Spain.
S ScheireUpper Airways Research Laboratory, Department of Head and Skin, Ghent University, Ghent, Belgium.
V BackerDepartment of Otorhinolaryngology, Head & Neck Surgery, and Audiology, Rigshospitalet, Copenhagen University, Copenhagen, Denmark.
M BlaissMedical College of Georgia at Augusta University, Augusta, GA, United States.
L O CardellDivision of ENT Diseases, Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
W De YunDepartment of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
A K EllisDivision of Allergy & Immunology, Department of Medicine, Queen's University, Kingston, ON, Canada.
W FokkensDepartment of Otorhinolaryngology, Amsterdam University Medical Centres, Amsterdam, Netherlands.
A T FoxGuy's & St Thomas' Hospitals NHS Foundation Trust, London, United Kingdom.
T Gilbert KruzPatient Advisory Board, European Forum for Research and Education in Allergy and Airway Diseases, Brussels, Belgium.
S HalkenHans Christian Andersen Children's Hospital, Odense University Hospital, Odense, Denmark.
P W HellingsEscuela de Doctorado UAM, Centro de Estudios de Posgrado, Universidad Autónoma de Madrid, Calle Francisco Tomás y Valiente, no. 2, Ciudad Universitaria de Cantoblanco, Madrid, Spain.
V HoxDepartment of Otorhinolaryngology, Cliniques Universitaires Saint Luc, Brussels, Belgium.
L KalogjeraDepartment of Otorhinolaryngology/Head and Neck Surgery, University Hospital Centre "Sestre milosrdnice", Zagreb School of Medicine, Zagreb, Croatia.
S LauDepartment of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité Universitätsmedizin Berlin, Berlin, Germany.
S MarinhoAllergy Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust and The University of Manchester, Manchester, United Kingdom.
M McDonaldThe Allergy Clinic, Johannesburg, South Africa.
R MösgesClinCompetence Cologne GmbH, Cologne, Germany.
J MullolRhinology Unit & Smell Clínic, Department of Otorhinolaryngology, Hospital Clínic Barcelona, Universitat de Barcelona; FRCB-IDIBAPS; CIBERES, Barcelona, Catalonia, Spain.
S NasserCambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.
R PawankarDepartment of Pediatrics, Nippon Medical School, Bunkyo-ku, Tokyo, Japan.
D PriceObservational and Pragmatic Research Institute, Singapore, Singapore.
D RyanUsher Institute, University of Edinburgh, Edinburgh, Scotland.
G ScaddingAllergy Department, Royal Brompton Hospital, London, United Kingdom.
P SmithGriffth University, Southport, QLD, Australia.
M Sosa KostrábováPatient Advisory Board, European Forum for Research and Education in Allergy and Airway Diseases, Brussels, Belgium.
M Vazquez-OrtizSection of Inflammation, Repair and Development, National Heart and Lung Institute, Imperial College London, London, United Kingdom.
U WahnCharite University Medicine, Berlin, Germany.
L ZhangDepartment of Otolaryngology Head and Neck Surgery and Department of Allergy, Beijing TongRen Hospital, Capital Medical University, Beijing, China.
P GevaertUpper Airways Research Laboratory, Department of Head and Skin, Ghent University, Ghent, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Allergic rhinitis (AR), the most prevalent immunological disease, affects approximately 400 million individuals globally and can significantly impact quality of life (QoL). Despite nearly 25 years of guidelines, AR remains largely under- diagnosed, suboptimally treated and poorly controlled. In the light of new knowledge and treatment options, there is a necessity to update or revise fundamental AR definitions to facilitate communication across diverse specialties engaged in its treatment and to improve patient care. The European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) convened a meeting of experts and patient representatives to deliberate the optimal methodology for measuring AR treatment responses and establishing novel treatment goals. This paper presents a consensus on revised AR definitions, including control, severe allergic rhinoconjunctivitis (SARC), refractory severe allergic rhinoconjunctivitis (R-SARC), remission, resolution, improvement, exacerbation, treatable traits (TTs), treat to target, relapse, progression, disease modification, and prevention.

Indexed as

allergen immunotherapy (AIT)allergic rhinitisbiologicscontroldefinitionsquality of liferefractory severe allergic rhinoconjunctivitis (R-SARC)severe allergic rhinoconjunctivitis (SARC)

Identifiers

PMID39963330
PMCPMC11830706

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.